- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00344981
Safety and Durability ofTenofovir and a Cell Cycle Agent for Viral Suppression (HADIT)
A Study to Probe The Safety And Durability of Tenofovir And a Cell Cycle Agent to Maintain Viral Suppression
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a 48 week open-label, randomized study comparing the safety and durability of a highly active de-intensified therapy (Tenofovir/Hydroxyurea) to a simplified standard of care therapy (Tenofovir plus 3TC or Emtriva plus Sustiva or Nevirapine) to maintain a durable viral suppression.
Up to 20 subjects with chronic HIV-1 infection, suppressed on highly active antiretroviral therapy, and without evidence of viral resistance will be enrolled in this study. Their present HAART therapy will be stopped.
Half of the 20 volunteers will be randomized to the Tenofovir 300 mg qd/Hydroxyurea 500mg qd arm and those subjects will have Hydroxyurea added to their current screening regimen for 4 weeks prior to de-intensifying to Hydroxyurea and Tenofovir. The other half will be randomized to Sustiva 600 mg qd or Nevirapine 200 mg twice a day); Tenofovir 300 mg qd, 3TC 300 mg qd or Emtriva 200 mg once a day. Volunteers will continue on this regimen for 48 weeks. Patients will be monitored for immunological and virological parameters as well as the incidence of toxicity and side effects during the study. If a patient's viral load reaches >400 copies/ml on 3 consecutive measurements over a 6 week period, they will be terminated from the study and started back on their HAART.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Maryland
-
Baltimore, Maryland, United States, 21201
- University of Maryland, Institute of Human Virology
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Diagnosis of HIV infection based on western blot testing, ELISA, or HIV viral load
- Age greater than or equal to 18 years
- CD4 count greater than or equal to 200c/ml.
- On a standard HAART regimen of 2 or 3 nucleoside reverse transcriptase inhibitors and either a protease inhibitor or a nonnucleoside reverse transcriptase inhibitor or 3 nucleoside reverse transcriptase inhibitors (2-3NRTI's + PI or 2-3NRTI's +NNRTI or 3NRTI's).
- On stable, continuous HAART regimen for greater than or equal to 3 months,
- Viral load less than or equal to 400c/ml on all measurements in the preceding 6 months with at least 2 measurements (screening viral load can be included if needed)
- Viral load less than or equal to 50c/ml at screening
- Subject able to comply with the study protocol
- Signed informed consent
- No history of antiretroviral failure that is suspected to be from or resulted in antiretroviral resistance.
Exclusion Criteria:
- Serious HIV related or non HIV related carcinoma requiring chemotherapy
- Recent serious opportunistic infection, such as progressive multifocal leukoencephalopathy, CMV disease, cryptococcus meningitis, cerebral toxoplasmosis, but not excluding other infections in which successful treatment may be judged to be placed at risk if antiretroviral therapy was de intensified.
- Known or suspected intolerance or hypersensitivity to Hydroxyurea
- Grade 3 or higher neutropenia (using ACTG grading table)
- Grade 2 or higher thrombocytopenia (using ACTG grading table)
- Grade 2 or higher LFT abnormalities (using ACTG grading table)
- History of pancreatitis, or risk factors associated with pancreatitis (more then two drinks containing alcohol/day, triglyceride levels greater than 400, and pancreatic enzymes greater then 1.5x normal)
- Renal insufficiency (Estimated Creatinine clearance of <60ml/min.)
- Chronic diarrhea
- Pregnancy or breastfeeding
- Unwillingness to use effective barrier contraception or abstinence
- The use of systemic corticosteroids, or other systemic immunosuppressive medications; the use of cholestyramine; the use of probenecid or other inhibitors of renal tubular secretion
- Genotypic or phenotypic testing documenting major resistance to any antiretroviral agents
- Active substance or mental health concerns that are judged to place a significant limitation on medication adherence.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Loss of viral suppression during maintenance therapy, defined by 3 consecutive viral load measurements greater than 50c/ml over a 48- week period.
Time Frame: At any point during the 48 week study
|
Viral load measurements will be done throughout the study to monitor for viral suppression
|
At any point during the 48 week study
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Laboratory Abnormalities: Routine measurements of hematology, serum chemistry, CD4 cell count, lipid profiles, and HIV-1 viral load will be performed. Viral genotypes will be performed with failure to maintain viral suppression.
Time Frame: Throughout the 48 week study
|
These tests will be done to monitor Safety and tolerability
|
Throughout the 48 week study
|
Collaborators and Investigators
Investigators
- Principal Investigator: Robert R. Redfield, MD, University of Maryland, School of Medcine, Department of Infectious Disease
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- RNA Virus Infections
- Virus Diseases
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Sexually Transmitted Diseases, Viral
- Sexually Transmitted Diseases
- Lentivirus Infections
- Retroviridae Infections
- Immunologic Deficiency Syndromes
- Immune System Diseases
- HIV Infections
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Reverse Transcriptase Inhibitors
- Nucleic Acid Synthesis Inhibitors
- Enzyme Inhibitors
- Anti-HIV Agents
- Anti-Retroviral Agents
- Antineoplastic Agents
- Antisickling Agents
- Tenofovir
- Hydroxyurea
Other Study ID Numbers
- H-22407
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV Infections
-
University of MinnesotaWithdrawnHIV Infections | HIV/AIDS | Hiv | AIDS | Aids/Hiv Problem | AIDS and InfectionsUnited States
-
University of California, San DiegoUniversity of California, Los Angeles; University of Southern California; California... and other collaboratorsCompleted
-
Gérond'ifRecruiting
-
University of California, DavisCompleted
-
University of California, San DiegoNational Center for Complementary and Integrative Health (NCCIH)CompletedHIV PositiveUnited States
-
University of ChicagoUniversity of Athens; National Development and Research Institutes, Inc.Completed
-
HIV Prevention Trials NetworkNational Institute on Drug Abuse (NIDA); National Institute of Allergy and...CompletedHIV PositiveIndonesia, Ukraine, Vietnam
-
University of ZimbabweCompleted
-
Florida International UniversityCompleted
-
Boston Children's HospitalNational Institute on Minority Health and Health Disparities (NIMHD)Completed
Clinical Trials on Tenofovir
-
National Institute of Allergy and Infectious Diseases...Microbicide Trials NetworkCompletedHIV InfectionsSouth Africa, Uganda, Zimbabwe
-
CONRADNational Institute of Allergy and Infectious Diseases (NIAID)Completed
-
National Institute of Allergy and Infectious Diseases...Microbicide Trials NetworkCompleted
-
Mahidol UniversityRecruitingRenal Insufficiency | TenofovirThailand
-
French National Agency for Research on AIDS and...Gilead Sciences; PharmassetTerminatedHBe Negative Chronic Hepatitis B | Hepatitis B Viral InfectionFrance
-
AIDS Clinical Trials GroupNational Institute of Allergy and Infectious Diseases (NIAID)RecruitingHIV InfectionsUnited States
-
National Institute of Allergy and Infectious Diseases...Eunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsCompletedHIV InfectionsUnited States, Puerto Rico
-
Eastern Virginia Medical SchoolGilead Sciences; United States Agency for International Development (USAID); FHI... and other collaboratorsActive, not recruitingAdherence, Medication | Acceptability of Health CareSouth Africa, Zimbabwe
-
CONRADEastern Virginia Medical School; University of North Carolina; Agility Clinical...Completed
-
Merck Sharp & Dohme LLCCompleted